Kangmei Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600518.SS

Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2023: 1.45%

Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) is 1.45% for the year ending December 31, 2023, a 103.75% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2022 was -38.78%, a -148.62% change year over year.
Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2021 was 79.76%, a -72.97% change year over year.
Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2020 was 295.14%, a 1,400.66% change year over year.
Kangmei Pharmaceutical Co., Ltd. Return on Equity (ROE) for the year ending December 31, 2019 was -22.69%, a -1,674.53% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Shanghai Stock Exchange: 600518.SS

Kangmei Pharmaceutical Co., Ltd.

CEO	Mr. Guowei Liu
IPO Date	March 19, 2001
Location	China
Headquarters	East side of Jieshen Road
Employees	4,409
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.

Key trends

Past 5 years